Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

Las Vegas
28:15

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Quality Improvement in Cancer Care: Why Is QI a Critical Process in Oncology? How to Understand the PDSA Cycle?

FEATURING Bernard Tawfik
  • 2 views
  • December 22, 2020
19:19

Total Health

2020 ASCO Update on Recurrent Ovarian Cancer: Does Secondary Cytoreductive Surgery Impact Patients Favorably?

FEATURING Carolyn Muller
  • 15 views
  • October 13, 2020
07:40

Total Health

2020 ASCO Update on Platinum Sensitive, Relapsed Ovarian Cancer: Is There an OS Benefit With Maintenance PARPi?

FEATURING Carolyn Muller
  • 339 views
  • October 13, 2020
  • 3
09:08

Total Health

PARPi Efficacy in Recurrent Platinum Sensitive Ovarian Cancer: Is Olaparib More Effective as Mono or Combination Therapy?

FEATURING Carolyn Muller
  • 118 views
  • October 13, 2020
  • 1
08:07

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on R/R AML: Is AMG 330 Safe and Tolerable?

FEATURING Michael Deininger
  • 106 views
  • October 12, 2020
  • 1
10:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Newly Diagnosed AML: How Safe Is ENA+AZA Combination and What Is the Effect on ORR in mIDH2 Disease?

FEATURING Michael Deininger
  • 72 views
  • October 12, 2020
06:41

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IDH1-Mutated AML: How Tolerated is IVO/VEN/AZA Combination and What Are the Survival Outcomes?

FEATURING Michael Deininger
  • 51 views
  • October 12, 2020
09:47

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on CML: How Does Ponatinib Dose Reduction Affect Response in CP Disease?

FEATURING Michael Deininger
  • 354 views
  • October 12, 2020
  • 3
12:13

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on PSMA in Prostate Cancer: Is 18F-DCFPyL PET/CT Superior to Standard Imaging?

FEATURING Nicholas Vogelzang
  • 8 views
  • September 30, 2020
19:36

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on nmCRPC: Does Enzalutamide Improve MFS/OS? How Is Darolutamide+ADT Combo Affecting Morbidity and Risk of Death?

FEATURING Nicholas Vogelzang
  • 9 views
  • September 30, 2020
10:06

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on HPV+ Oropharynx Cancer: Can TORS and Reduced Dose Post-Operative RT Maintain High Cure Rates and Decrease Late Toxicity in Intermediate Risk Disease?

FEATURING Deborah Wong
  • 3 views
  • September 29, 2020
13:56

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates for High-Risk SCCHN: Is Post-Operative Weekly Cisplatin 40mg/m2 Inferior to Bolus Cisplatin With RT?

FEATURING Deborah Wong
  • 25 views
  • September 29, 2020
17:05

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Solid H&N Tumors With HRAS Mutations: Is Tipifarnib a Good Option for Post-Chemo Patients With SCCHN? Does Axitinib Improve Overall Outcomes?

FEATURING Deborah Wong
  • 14 views
  • September 29, 2020
24:44

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on EGFR+ NSCLC: Adjuvant Gefitinib, Adjuvant Osimertinib, Bevacizumab + Erlotinib Final Survival Analysis

FEATURING Shayma Kazmi
  • 94 views
  • September 22, 2020
09:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IO in Advanced NSCLC: Nivo/Ipi + 2 Cycles of Chemo vs. 4 Cycles of Chemo - Did OS Improve?

FEATURING Shayma Kazmi
  • 97 views
  • September 22, 2020
08:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ NSCLC: Did Trastuzumab Deruxtecan Demonstrate Favorable Clinical Activity?

FEATURING Shayma Kazmi
  • 390 views
  • September 22, 2020
  • 2
13:17

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Post anti-PD-1 Options in Advanced Melanoma: Can We Have an Effective Regimen With the Addition of Low-Dose Ipi to Pembro?

FEATURING Zeynep Eroglu
  • 49 views
  • August 13, 2020
16:32

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Neoadjuvant Melanoma: Neoadjuvant Ipi/Nivo or Adjuvant Ipi/Nivo? What Is the Optimal Dosing of the Neoadjuvant Combination?

FEATURING Zeynep Eroglu
  • 236 views
  • August 13, 2020
  • 1
08:58

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Adjuvant Therapy in Stage III Melanoma: Is There a RFS Benefit to Adjuvant Pembrolizumab in Resected High-Risk Disease? What Is the Benefit of Dab + Tram in BRAF V600E / V600K Melanoma?

FEATURING Zeynep Eroglu
  • 47 views
  • August 13, 2020
07:16

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updated BEACON Results on BRAF V600E mCRC: Is the FDA Approval of Encorafenib + Cetuximab Practice Changing?

FEATURING Richard Kim
  • 320 views
  • August 20, 2020
  • 2
05:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Pembro vs. Chemo in 1L dMMR / MSI-H mCRC: Did Results of KEYNOTE-177 Confirm a New SoC?

FEATURING Richard Kim
  • 397 views
  • August 13, 2020
  • 1
07:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mCRC: Can 3L T-DXd Be Effective in HER2+ Disease?

FEATURING Richard Kim
  • 299 views
  • August 20, 2020
  • 1
05:15

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage III Rectal Cancer: Neoadjuvant Short-Course RT Followed by Chemo Before TME vs. SoC - Which Option Offer a Better Outcome?

FEATURING Richard Kim
  • 918 views
  • August 20, 2020
  • 2
06:14

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Rectal Adenocarcinoma: Can Patients With a cCR to Neoadjuvant Therapy Skip Surgery and Safely Follow a WW Protocol With the Ultimate Goal of Achieving Organ Preservation?

FEATURING Richard Kim
  • 1,187 views
  • August 20, 2020
  • 7
08:01

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on SCLC: Can a Higher TRT-Dose Prolong Survival in LS-SCLC? Is IP Superior to EP in RFS for Patients With Completely Resected HGNEC?

FEATURING Sandip Patel
  • 201 views
  • August 24, 2020
07:39

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Localized NSCLC: Does the Addition of Pembro to CCRT Increase Antitumor Activity? Gefitinib vs. Adjuvant Chemotherapy - Does the Duration of Therapy Matter in the Curative Setting?

FEATURING Sandip Patel
  • 231 views
  • August 7, 2020
  • 1
06:39

2020 ASCO Virtual Direct™ Highlights

Adjuvant Therapy in Resectable NSCLC: What Does ADAURA Data Suggest on Osimertinib in EGFR+ Disease?

FEATURING Sandip Patel
  • 161 views
  • August 24, 2020
  • 1
08:11

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Rare Melanoma Types: Is Anti-PD-1 + VEGFi Axitinib Effective in Mucosal Melanoma?

FEATURING Zeynep Eroglu
  • 28 views
  • August 13, 2020